Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Details : Tarcidomgen Kimleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 19, 2024